Drug
Divarasib clinical trials
Also written GDC-6036.
- studies test it
- 12
- open now
- 5
- in phase 3
- 4
- first study started
- 2017
Keep track of what changes. Save the divarasib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 4
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Often tested with
Tested in the same studies.
Atezolizumab (4) · Entrectinib (3) · Alectinib (3) · Inavolisib (2) · Pralsetinib (2) · Cobimetinib (2) · Vemurafenib (2) · Bevacizumab (2)
Studies
Open first, then newest update. How each study uses divarasib is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)RecruitingPhase 2Genentech, Inc.NCT04302025Written as Divarasib
- A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 3Hoffmann-La RocheNCT07541170Written as Divarasib
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)RecruitingPhase 1Hoffmann-La RocheNCT04929223Written as Divarasib
- A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C MutationRecruitingPhase 1/2Hoffmann-La RocheNCT05789082Written as Divarasib
- A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerRecruitingPhase 3Hoffmann-La RocheNCT06793215Written as Divarasib
- A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingPhase 3Hoffmann-La RocheNCT06497556Written as Divarasib
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingPhase 2Hoffmann-La RocheNCT04589845Written as Divarasib
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 2/3Hoffmann-La RocheNCT03178552Written as Divarasib
- A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic FunctionCompletedPhase 1Genentech, Inc.NCT06734208Written as Divarasib
- A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy ParticipantsCompletedPhase 1Genentech, Inc.NCT06835465Written as Divarasib
- A Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Divarasib in Healthy ParticipantsCompletedPhase 1Genentech, Inc.NCT06690138Written as Divarasib
- A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy ParticipantsCompletedPhase 1Genentech, Inc.NCT06677957Written as Divarasib
Given in every arm · 2 — divarasib is usual care beside what is tested
- A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyRecruitingPhase 3Hoffmann-La RocheNCT05862285Written as Divarasib
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C MutationActive, not recruitingPhase 1Genentech, Inc.NCT04449874Written as GDC-6036
Codes
What other systems call divarasib · ClinicalTrials.gg INT016425
- UNII (FDA) E6S21PVT91DIVARASIBConfirmed FDA, Wikidata
- Wikidata Q123118541divarasibConfirmed FDA, Wikidata
- NCI Thesaurus C173995DivarasibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | E6S21PVT91 | DIVARASIB | Confirmed FDA, Wikidata |
| Wikidata | Q123118541 | divarasib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C173995 | Divarasib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.